{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:32:51Z","timestamp":1761863571500,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Cetuximab is a monoclonal antibody against epidermal growth factor receptor with activity against head and neck cancer and colorectal cancer. Anaphylaxis in response to cetuximab is a significant clinical problem in the Southeastern United States with a grade 3\/4 infusion reaction rate of 14%. Previous retrospective data have suggested that the presence of preformed immunoglobulin E antibodies against galactose\u2010\u03b1\u20101,3\u2010galactose in serum can predict anaphylaxis in response to cetuximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Sixty patients were prospectively screened as part of the entry criteria for a phase 2 study of neoadjuvant carboplatin, nab\u2010paclitaxel, and cetuximab. Patients were recruited at 2 academic medical centers known to have high anaphylaxis rates: the University of North Carolina and Vanderbilt. Only patients with a negative laboratory result were treated on the clinical protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>No patient experienced anaphylaxis; the negative predictive value was thus 100%. Other than smoking history, the demographics were similar for assay\u2010positive subjects and assay\u2010negative subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Subjects with a negative test result can be safely treated with cetuximab. Further research is required regarding the optimal cutoff for positivity and the positive predictive value. <jats:bold><jats:italic>Cancer<\/jats:italic> 2016;122:1697\u2010701<\/jats:bold>. \u00a9 <jats:italic>2016 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29978","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T21:12:07Z","timestamp":1458335527000},"page":"1697-1701","source":"Crossref","is-referenced-by-count":20,"title":["Using the galactose\u2010\u03b1\u20101,3\u2010galactose enzyme\u2010linked immunosorbent assay to predict anaphylaxis in response to cetuximab"],"prefix":"10.1002","volume":"122","author":[{"given":"Jared","family":"Weiss","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juneko","family":"Grilley Olson","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison Mary","family":"Deal","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhishamjit","family":"Chera","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Weissler","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Vanderbilt\u2010Ingram Cancer Center Nashville Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Neil","family":"Hayes","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Vanderbilt\u2010Ingram Cancer Center Nashville Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Cetuximab [package insert]. Indianapolis IN: Eli Lilly & Co;2012."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1193"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071834"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.7812"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213510542"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"volume-title":"Paper presented at: 3rd AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development","year":"2008","author":"Robinson D","key":"e_1_2_8_9_1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.02.019"},{"key":"e_1_2_8_11_1","unstructured":"Centers for Disease Control and Prevention.Lone star tick a concern but not for Lyme disease.http:\/\/www.cdc.gov\/stari\/disease\/. Accessed June 5 2015."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.333"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu141"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70181-5"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.09.046"},{"key":"e_1_2_8_16_1","first-page":"72","article-title":"Managing cetuximab hypersensitivity\u2010infusion reactions: incidence, risk factors, prevention, and retreatment","volume":"8","author":"George TJ","year":"2010","journal-title":"J Support Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29978","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:25:29Z","timestamp":1760282729000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/cncr.29978"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29978","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}